Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals stock opened at $0.10 on Monday. The company’s fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.30. The stock has a market capitalization of $4.31 million, a PE ratio of -0.01 and a beta of 1.51. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.